Drug Profile
Fluorine-18-THK 5351
Alternative Names: 3H-THK5351; [18F]THK-5351; F-18 THK-5351; FluoroTau; GE-216Latest Information Update: 02 Jan 2023
Price :
$50
*
At a glance
- Originator Tohoku University
- Developer Chang Gung Memorial Hospital; Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; GE Healthcare; Tohoku University
- Class Imaging agents; Pyridines; Quinolines; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
- Phase II Cognition disorders; Neurodegenerative disorders
- No development reported Aphasia; Lewy body disease; Mild cognitive impairment; Progressive supranuclear palsy
Most Recent Events
- 02 Jan 2023 Phase-III development is ongoing in Belgium (IV) (EudraCT2016-001436-35)
- 05 Oct 2021 Phase-II development is ongoing in Taiwan (NCT04588649)
- 23 Oct 2020 Chang Gung Memorial Hospital completes a phase II trial in Vascular dementia (Diagnosis, In adults, In elderly) in Taiwan (NCT04588649)